INTELLIA THERAPEU DL-,01 WKN: A2AG6H ISIN: US45826J1051 Kürzel: NTLA Forum: Aktien Thema: Hauptdiskussion

Danke für die News

https://finance.yahoo.com/news/intellia-therapeutics-awarded-innovation-passport-123000562.html

Haben die über 100 mio Aktien im Umlauf? 🤔

Naja die kann auch noch auf 10€ runterfallen. Weiß jemand wieviele Aktien derzeit im Umlauf sind.? Die geben ja immer mehr Aktien raus. Wieviele Aktien waren auf dem Markt vor 5 Jahren? Stehen in 2023 irgendwelche wichtigen Studienergebnisse an?

Zieht mal im 5 Jahreschart die Trendlinie ab Mitte 2020. Ich denke jetzt ist ein guter Einstieg

Intellia Therapeutics Announces Proposed Public Offering of Common Stock https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-announces-proposed-public-offering-3

https://www.fiercebiotech.com/biotech/intellia-ready-talk-functional-cure-hae-interim-data-hand-second-gene-editing-candidate

https://www.globenewswire.com/news-release/2022/11/03/2547478/0/en/Intellia-Therapeutics-Announces-Third-Quarter-2022-Financial-Results-and-Highlights-Recent-Company-Progress.html

https://www.globenewswire.com/news-release/2022/10/31/2544470/0/en/Intellia-Therapeutics-to-Present-Updated-Interim-Clinical-Data-from-Ongoing-Phase-1-2-Study-of-NTLA-2002-for-the-Treatment-of-Hereditary-Angioedema-at-the-2022-ACAAI-Annual-Scienti.html

🎈

Intellia Investors Are Dumping Stock on News of Crispr Gene-Editing Success https://www.shareandstocks.com/intellia-investors-are-dumping-stock-on-news-of-crispr-gene-editing-success/

Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2002, an Investigational CRISPR Therapy for the Treatment of Hereditary Angioedema https://www.globenewswire.com/news-release/2022/09/01/2508902/0/en/Intellia-Therapeutics-Receives-U-S-FDA-Orphan-Drug-Designation-for-NTLA-2002-an-Investigational-CRISPR-Therapy-for-the-Treatment-of-Hereditary-Angioedema.html • NTLA-2002, an in vivo genome editing candidate designed to prevent angioedema attacks in patients with hereditary angioedema (HAE) after a single dose, is currently being evaluated in a Phase 1/2 study ...

https://www.globenewswire.com/news-release/2022/08/23/2503154/0/en/Intellia-Therapeutics-to-Present-Interim-Clinical-Data-from-Ongoing-Phase-1-2-Study-of-NTLA-2002-for-the-Treatment-of-Hereditary-Angioedema-at-the-2022-Bradykinin-Symposium.html

Intellia Therapeutics down 12% following bottom line Q2 earnings miss https://seekingalpha.com/news/3867319-intellia-therapeutics-down-12-following-bottom-line-q2-earnings-miss?source=content_type%3Areact%7Cfirst_level_url%3Amarket-news%7Csection_asset%3Amain • Intellia Therapeutics (NASDAQ:NTLA) is down 12% in Thursday morning trading after it missed analyst estimates on Q2 2022 EPS. • The company's net loss in the quarter widened ~46% to ~$100.7M compared to the prior-year period (-$1.33 per share, basic and diluted vs. $1.01). • Revenue of ~$14M, a 114% year-over-year increase, was a beat. • Intellia (NTLA) was weighed down in the quarter by a significant increase in operating expenses, which went up ~49% to $112.3M. R&D expenses alone rose 53% to ~$90.2M. • The company ended the quarter with $906.9M in cash and cash equivalents compared to compared to $1.1B on Dec. 31, 2022.

Das ist der Grund für den heftigen Kursrückgang heute: https://www.fiercebiotech.com/biotech/intellia-looks-tack-lower-dose-polyneuropathy-trial-arm-after-elevated-liver-levels

Gestern ging es halt ordentlich aufwärts ohne news (und wohl befeuert durch Alnylam). Mal schauen, wo sie sich heute 'einpendelt'.